Miriam Dervan, founder & CEO of mdgroup, explains how treating patient experience as a strategic investment—rather than a ...

Mike Wenger, chief innovation officer at CRIO, discusses how different site types—from academic medical centers to ...

Sustained “boots-on-the-ground” community engagement, beyond digital recruitment campaigns, was positioned as a primary lever to improve trial equity and representation. Hesitancy to discuss diversity ...

Holly Leslie, vice president of services at Ledger Run, explains why site selectivity is not yet universal, but increasingly ...

Otis Johnson, PhD, MPA, founder and principal consultant at Vantix Operations, discusses how ESG is evolving from a reporting ...

Efficiency and accelerating clinical trial timelines have emerged as key themes at this year’s annual SCOPE Summit in Orlando, FL. The opening keynote panel of the event moderated by Jeremy Goldberg, ...

Getz K, Barr E. Aligning Purpose, Innovation, and Operational Excellence in Clinical Development. SCOPE Summit 2026. February 3, 2026. Stay current in clinical research with Applied Clinical Trials, ...

Charlie Paterson, partner at PA Consulting, outlines how limited FDA guidance on innovative designs, decentralized models, ...

Raja Shankar, VP of machine learning at IQVIA, explains how AI-driven trial simulation and automation are beginning to influence decision-making across every phase of clinical development.

Holly Leslie, vice president of services at Ledger Run, explains why site selectivity is not yet universal, but increasingly driven by larger, more sophisticated sites that are demanding stronger ...

Today's biopharmaceutical landscape demands a fundamental rethinking of outsourcing approaches that embrace collaboration, flexibility, and teams willing to meet halfway.

Some organizations are considering ex-US studies for initial phases. Even with initiatives like the single pivotal trial concept, confidence requirements may still demand larger samples and longer ...